ライフサイエンスコーパス: aspergillosis

1 antibody detection for chronic and allergic aspergillosis.

2 for PTX3 SNPs modifying the risk of invasive aspergillosis.

3 remaining 165 patients no invasive pulmonary aspergillosis.

4 lent in a murine model of invasive pulmonary aspergillosis.

5 CGD mice from colitis and also from invasive aspergillosis.

6 ich remains the diagnostic gold standard for aspergillosis.

7 uced virulence in a murine model of invasive aspergillosis.

8 antification for early detection of invasive aspergillosis.

9 ransplant recipients with invasive pulmonary aspergillosis.

10 treatment failure in patients with invasive aspergillosis.

11 potential source of azole-resistant invasive aspergillosis.

12 ithm judged 86 of 115 cases to have putative aspergillosis.

13 eria classified these as "probable" invasive aspergillosis.

14 unocompromised patients who develop invasive aspergillosis.

15 detrimental immunopathology that is seen in aspergillosis.

16 se of the more commonly encountered invasive aspergillosis.

17 pathology-controlled patients, 79 had proven aspergillosis.

18 spergillus fumigatus, the causative agent of aspergillosis.

19 in patients with triazole-resistant invasive aspergillosis.

20 Four patients had allergic bronchopulmonary aspergillosis.

21 asthma that mimics allergic bronchopulmonary aspergillosis.

22 causative agent of life-threatening invasive aspergillosis.

23 s fumigatus is responsible for most cases of aspergillosis.

24 not protect immunosuppressed recipients from aspergillosis.

25 d mice from experimentally induced pulmonary aspergillosis.

26 hogenic fungus Aspergillus fumigatus, called aspergillosis.

27 al disseminated candidiasis and inhalational aspergillosis.

28 distinct murine models of invasive pulmonary aspergillosis.

29 genously disseminated and invasive pulmonary aspergillosis.

30 ent of the life-threatening disease invasive aspergillosis.

31 ificant challenge in effective management of aspergillosis.

32 ating improved outcomes of treating invasive aspergillosis.

33 -treated BALB/c mice with cutaneous invasive aspergillosis.

34 ro and in mouse models of invasive pulmonary aspergillosis.

35 contributes to pathogenesis during invasive aspergillosis.

36 is and are used clinically to treat invasive aspergillosis.

37 virulence in an experimental murine model of aspergillosis.

38 ericin B formulation as therapy for invasive aspergillosis.

39 eroid-immunosuppressed mice against invasive aspergillosis.

40 istic in the treatment of invasive pulmonary aspergillosis.

41 nd, in turn, host susceptibility to invasive aspergillosis.

42 den in a neutropenic mouse model of invasive aspergillosis.

43 e the diagnosis of allergic bronchopulmonary aspergillosis.

44 CRI protocols in an animal model of invasive aspergillosis.

45 modulatory therapy to improve the outcome of aspergillosis.

46 se fungal rhinosinusitis or bronchopulmonary aspergillosis.

47 atus avirulent in a mouse model of pulmonary aspergillosis.

48 r in vitro or in a murine model of pulmonary aspergillosis.

49 8 eyes of 8 patients with isolated, orbital aspergillosis.

50 mprehension of the pathogenesis of pulmonary aspergillosis.

51 ausative agent of allergic broncho-pulmonary aspergillosis.

52 vancement in the diagnosis and management of aspergillosis.

53 crease in the 3-year probability of invasive aspergillosis (12% vs. 1%, P=0.02) and death that was no

54 ), 79 patients had proven invasive pulmonary aspergillosis (15.1%).

55 y type of IFI included 7 of 12 with invasive aspergillosis, 2 of 2 with invasive fusariosis, 1 of 1 w

56 gorithm judged 199 patients to have putative aspergillosis (38.0%) and 246 to have Aspergillus coloni

57 udy Group criteria, 32 patients had probable aspergillosis (6.1%) and 413 patients were not classifia

58 Of 34 patients with orbital aspergillosis, 8 (23.5%) had isolated orbital involvemen

59 igatus) is the most common cause of invasive aspergillosis, a frequently fatal lung disease primarily

60 e displayed high susceptibility to pulmonary aspergillosis, a phenotype associated with a proinflamma

61 Aspergillus fumigatus causes invasive aspergillosis, a potentially fatal infection in oncohema

62 t has previously been reported that invasive aspergillosis, a prototypic opportunistic infection in n

63 o the diagnosis of allergic bronchopulmonary aspergillosis (ABPA) and fungal sensitisation, but how t

64 g diseases such as allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensi

65 ng to discriminate allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF).

66 illosis (CCPA) and allergic bronchopulmonary aspergillosis (ABPA) in overtly immunocompetent and atop

67 Allergic bronchopulmonary aspergillosis (ABPA) is caused by a dominant Th2 immune

68 Allergic bronchopulmonary aspergillosis (ABPA) is caused by A fumigatus and is cha

69 Allergic bronchopulmonary aspergillosis (ABPA) is characterized by an allergic imm

70 Although allergic bronchopulmonary aspergillosis (ABPA) leads to deterioration of pulmonary

71 nsitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function a

72 (CF) patients with allergic bronchopulmonary aspergillosis (ABPA).

73 s (S3 and S4) increased the risk of invasive aspergillosis (adjusted hazard ratio for S3, 2.20; 95% c

74 otype S4 also increased the risk of invasive aspergillosis (adjusted odds ratio, 2.49; 95% CI, 1.15 t

75 mmunity result in increased risk of invasive aspergillosis after chemotherapy or transplantation.

76 were shown to influence the risk of invasive aspergillosis among hematopoietic stem cell transplant r

77 BAL GM levels in the diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts.

78 y reflecting the low prevalence of pulmonary aspergillosis among nonimmunosuppressed patients.

79 lymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic hematopoiet

80 r TLR4 haplotype S4 and the risk of invasive aspergillosis among recipients of hematopoietic-cell tra

81 Incidences of invasive pulmonary aspergillosis, an infection caused predominantly by Aspe

82 r study involving 107 patients with invasive aspergillosis and 223 matched controls.

83 de invasive aspergillosis, chronic pulmonary aspergillosis and bronchitis.

84 y type I confer a predisposition to invasive aspergillosis and candidiasis.

85 fungal disease (IFD), particularly invasive aspergillosis and candidiasis.

86 f TLR3 was associated with susceptibility to aspergillosis and concomitant failure to activate memory

87 he role of TLR9 in murine models of invasive aspergillosis and fungal asthma.

88 se of allergic rhinosinusitis, postoperative aspergillosis and fungal keratitis.

89 multiplex real-time PCR capable of detecting aspergillosis and genetic markers associated with azole

90 the etiological agent of invasive pulmonary aspergillosis and had reduced in vitro susceptibilities

91 ion into account, reliably detected invasive aspergillosis and may be a promising diagnostic tool for

92 gets for the treatment of invasive pulmonary aspergillosis and may potentiate both innate immunity an

93 It is approved for the treatment of invasive aspergillosis and mucormycosis.

94 Invasive aspergillosis and other fungal infections occur in immun

95 Rare instances of aspergillosis and other mycoses, including agents of muc

96 more, nosocomial infections such as invasive aspergillosis and Pseudomonas aeruginosa occurred during

97 highlights the magnitude of azole-resistant aspergillosis and resistance mechanisms implicated in th

98 ood conditions are allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitizatio

99 spergillus include allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitizatio

100 seen, and 1 trial indicated a lower rate of aspergillosis and survival benefits in patients with AML

101 about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics

102 aspergillosis, chronic necrotizing pulmonary aspergillosis, and aspergilloma.

103 ors (e.g., asthma, allergic bronchopulmonary aspergillosis, and chronic obstructive pulmonary disease

104 Enterobacter bacteremia, invasive aspergillosis, and disseminated Candida infections were

105 lammatory response during invasive pulmonary aspergillosis, and in particular the IL-1 axis, drives t

106 chondrial respiration in the pathogenesis of aspergillosis, and lay the foundation for future researc

107 of asthma, croup, allergic bronchopulmonary aspergillosis, and subglottic hemangioma.

108 , the use of molecular (PCR) diagnostics for aspergillosis, and the crucial role of antibody detectio

109 med, radiology data consistent with invasive aspergillosis, and the timing of initiation of antifunga

110 N-gamma in the lungs in neutropenic invasive aspergillosis, and this is an important mechanism in the

111 treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent d

112 ective in reducing the incidence of invasive Aspergillosis as compared with no prophylaxis.

113 proven or probable IA from patients without aspergillosis, as determined by European Organization fo

114 is particularly true for invasive pulmonary aspergillosis, as so far, sources of (macro)elements tha

115 We developed invasive aspergillosis (Aspergillus fumigatus) and mucormycosis (

116 e of IFD, invasive candidiasis, and invasive aspergillosis at 1 year.

117 and validate novel methods for diagnosis of aspergillosis based on detection of galactomannan requir

118 patients without allergic broncho-pulmonary aspergillosis but sensitized to A. fumigatus and in nine

119 are important in the innate defense against aspergillosis, but little is known about their molecular

120 vaccine-induced protection from experimental aspergillosis, but the molecular mechanisms leading to t

121 mediate their protective effect in invasive aspergillosis by acting as the major source of IFN-gamma

122 as the potential to improve the diagnosis of aspergillosis by offering more rapid and sensitive ident

123 Invasive aspergillosis carries a high mortality with a rising pre

124 ability in the numbers of diagnosed invasive aspergillosis cases in oncology centers, and a persisten

125 This is the first description of canine aspergillosis caused by A. versicolor.

126 A recent report on several cases of invasive aspergillosis caused by Neosartorya udagawae suggested d

127 fumigatus causes chronic cavitary pulmonary aspergillosis (CCPA) and allergic bronchopulmonary asper

128 atus may result in allergic bronchopulmonary aspergillosis, chronic necrotizing pulmonary aspergillos

129 osis, two each with acute invasive pulmonary aspergillosis, chronic necrotizing pulmonary aspergillos

130 s of Aspergillus infections include invasive aspergillosis, chronic pulmonary aspergillosis and bronc

131 tive GM (serologic allergic bronchopulmonary aspergillosis); class 3 (n = 19, 14.6%) represented pati

132 recipients with proven or probable invasive aspergillosis collected as part of the Transplant-Associ

133 Chronic pulmonary aspergillosis (CPA) is an infectious disease that progre

134 CMC, invasive candidiasis, invasive aspergillosis, deep dermatophytosis, pneumocystosis, and

135 ves survival of mice with invasive pulmonary aspergillosis, demonstrating the potential of CalA as an

136 ally, in the context of neutropenic invasive aspergillosis, depletion of DCs resulted in impaired fun

137 Invasive aspergillosis develops in immunocompromised patients, an

138 The calibrator can be used to standardize aspergillosis diagnostic assays which detect and/or quan

139 In invasive pulmonary aspergillosis, direct invasion and occlusion of pulmonar

140 ortunistic animal and human pathogen causing aspergillosis diseases with incidence increasing in the

141 A case of fatal aspergillosis due to a TR46/Y121F/T289A azole-resistant

142 Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment fai

143 tis, and a new immunologic classification of aspergillosis emerged.

144 , pneumonia, secondary peritonitis, invasive aspergillosis, endocarditis and myocardial infarction.

145 In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against

146 gatus is the most frequent agent of invasive aspergillosis, followed by A. lentulus and A. viridinuta

147 h a potentially low pretest risk of invasive aspergillosis following effective antimold prophylaxis.

148 used as an aid in the diagnosis of invasive aspergillosis for almost 2 decades.

149 son clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole w

150 elped distinguish allergic broncho-pulmonary aspergillosis from A. fumigatus sensitization with good

151 s is still limited, mouse models of invasive aspergillosis fulfill a critical void for studying treat

152 efined in patients with GM-positive invasive aspergillosis (GPA).

153 echinocandins for the treatment of invasive aspergillosis has been based on historically controlled

154 Invasive aspergillosis has emerged as an important cause of morbi

155 Patients with invasive aspergillosis (IA) (3/3) had positive GM at baseline as

156 U) patients with probable or proven invasive aspergillosis (IA) and 100 ICU patients without IA.

157 211 samples from 10 proven/probable invasive aspergillosis (IA) and 2 possible IA cases and 27 contro

158 93 patients with proven or probable invasive aspergillosis (IA) and GM values of >or=0.50 from Januar

159 Outbreaks of invasive aspergillosis (IA) are believed to be caused by airborne

160 apy (cART), roughly 50% of cases of invasive aspergillosis (IA) associated with human immunodeficienc

161 Strict definition of invasive aspergillosis (IA) cases is required to allow precise co

162 NA extracts from 14 proven/probable invasive aspergillosis (IA) cases, 2 possible IA cases, and 33 co

163 The outcome of invasive aspergillosis (IA) continues to be associated with signi

164 Delayed diagnosis in invasive aspergillosis (IA) contributes to its high mortality.

165 Screening of high-risk patients for invasive aspergillosis (IA) has the potential to decrease the use

166 gies for the molecular detection of invasive aspergillosis (IA) have been established by the European

167 the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological patients r

168 ng is increasingly used to diagnose invasive aspergillosis (IA) in high-risk patients.

169 r lavage (BAL) for the diagnosis of invasive aspergillosis (IA) in lung transplant recipients is not

170 The most common cause of invasive aspergillosis (IA) in patients with chronic granulomatou

171 Despite suffering an outbreak of invasive aspergillosis (IA) in the intensive care unit due to ext

172 Invasive aspergillosis (IA) is a life-threatening infection for i

173 Invasive aspergillosis (IA) is a life-threatening systemic fungal

174 Invasive aspergillosis (IA) is a significant cause of morbidity a

175 Invasive aspergillosis (IA) is an important cause of morbidity an

176 Invasive aspergillosis (IA) is associated with poor outcomes in p

177 The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of diseas

178 Invasive aspergillosis (IA) remains a leading cause of morbidity

179 Invasive aspergillosis (IA) remains a leading cause of mortality

180 Diagnosis of invasive aspergillosis (IA) remains challenging.

181 Invasive aspergillosis (IA) resulting from infection by Aspergill

182 evastating infections after HSCT is invasive aspergillosis (IA), a life-threatening disease caused by

183 ansplant recipients are at risk for invasive aspergillosis (IA), associated with a significant mortal

184 otizing pulmonary aspergillosis, or invasive aspergillosis (IA), depending on the host's immune statu

185 four groups of patients: those with invasive aspergillosis (IA), those with other mold infections (Fu

186 long been used for the diagnosis of invasive aspergillosis (IA), variable performance in clinical pra

187 in neutropenic mice with invasive pulmonary aspergillosis (IA).

188 idely utilized for the diagnosis of invasive aspergillosis (IA).

189 galactomannan (GM) for diagnosing pulmonary aspergillosis in 73 nonimmunocompromised patients with p

190 but also triggers allergic bronchopulmonary aspergillosis in a subset of otherwise healthy individua

191 phylaxis trials have shown trends of reduced aspergillosis in BMT patients; however, no survival bene

192 Three distinct classes of aspergillosis in CF were identified by latent class anal

193 established serologic markers, to reclassify aspergillosis in CF.

194 he presentation and epidemiology of invasive aspergillosis in children and adolescents with acquired

195 y tract colonization from invasive pulmonary aspergillosis in critically ill patients.

196 Disseminated aspergillosis in dogs has been associated with Aspergill

197 re, we evaluated susceptibility to pulmonary aspergillosis in globally NADPH oxidase-deficient mice v

198 iciency is a novel susceptibility factor for aspergillosis in high-risk patients.

199 l pathogen causing life-threatening invasive aspergillosis in immunocompromised patients.

200 e been used for prophylaxis against invasive aspergillosis in lung transplant recipients.

201 mAb treatment is protective during invasive aspergillosis in neutropenic mice.

202 bsence of CCR7 is protective during invasive aspergillosis in neutropenic mice.

203 Pulmonary aspergillosis in nonimmunocompromised hosts, although ra

204 s and may contribute to the risk of invasive aspergillosis in patients treated with HSCT.

205 of great value in the clearance of invasive aspergillosis in patients with CGD.

206 in order of importance after candidiasis and aspergillosis in patients with hematological and allogen

207 ly associated with allergic bronchopulmonary aspergillosis in patients with severe asthma in which ch

208 The low pretest risk of invasive aspergillosis in the context of effective antimold proph

209 competent host but can cause lethal invasive aspergillosis in the immunocompromised host.

210 insights into the pathogenesis of pulmonary aspergillosis in the immunocompromised host.

211 ential mechanism for development of invasive aspergillosis in the setting of CGD and corticosteroid-i

212 olonization from putative invasive pulmonary aspergillosis in this patient group.

213 he performance of any PCR assay for invasive aspergillosis in whole blood or serum and that used the

214 ns expanded in patients with active invasive aspergillosis, indicating their contribution to infectio

215 ogeny of adaptive immune responses to murine aspergillosis infection in relation to vaccination.

216 t toxicity, including pulmonary and cerebral aspergillosis infections.

217 ailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal mening

218 s and optimal therapy for invasive pulmonary aspergillosis (IPA) after kidney transplantation (KT) re

219 Risk factors for invasive pulmonary aspergillosis (IPA) after kidney transplantation have be

220 fluid in the diagnosis of invasive pulmonary aspergillosis (IPA) among solid-organ transplant recipie

221 y on an LFD developed for invasive pulmonary aspergillosis (IPA) detection.

222 Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease c

223 Invasive pulmonary aspergillosis (IPA) is a significant complication after

224 olved inflammation during invasive pulmonary aspergillosis (IPA) is associated with a poor outcome.

225 Invasive pulmonary aspergillosis (IPA) is one of the major complications in

226 the causative organism in invasive pulmonary aspergillosis (IPA) is recommended.

227 Invasive pulmonary aspergillosis (IPA) is the most common manifestation, so

228 Diagnosis of invasive pulmonary aspergillosis (IPA) remains a major challenge to clinica

229 Invasive pulmonary aspergillosis (IPA) remains an important cause of morbid

230 ndard test for diagnosing invasive pulmonary aspergillosis (IPA).

231 al immunity in a model of invasive pulmonary aspergillosis (IPA).

232 gent for the treatment of invasive pulmonary aspergillosis (IPA).

233 to therapeutic failure in invasive pulmonary aspergillosis (IPA).

234 te the early diagnosis of invasive pulmonary aspergillosis (IPA).

235 d triazoles is antagonistic against invasive aspergillosis is a controversial issue that is not likel

236 Invasive aspergillosis is a deadly infection for which new antifu

237 Invasive aspergillosis is a difficult-to-diagnose infection with

238 Invasive pulmonary aspergillosis is a leading cause of infection-associated

239 Pulmonary aspergillosis is a lethal mold infection in the immunoco

240 Invasive aspergillosis is a life-threatening complication of neut

241 Invasive aspergillosis is a major threat to patients with chronic

242 Invasive aspergillosis is a serious infectious complication after

243 Invasive aspergillosis is among the most common human fungal infe

244 Diagnosis of invasive aspergillosis is challenging and delays in treatment are

245 Invasive aspergillosis is characterized by hyphal invasion of the

246 The diagnosis of pulmonary aspergillosis is difficult, since the recovery of Asperg

247 Invasive aspergillosis is often a consequence of immune suppressi

248 Allergic bronchopulmonary aspergillosis is often difficult to treat and results in

249 Allergic bronchopulmonary aspergillosis is one of the most severe A. fumigatus-rel

250 hough the number of cases of azole-resistant aspergillosis is still limited, resistance mechanisms co

251 the strategies to improve the management of aspergillosis is the adoptive transfer of antigen-specif

252 SNPs) in PTX3 to the development of invasive aspergillosis is unknown.

253 d that in a murine model of bronchopulmonary aspergillosis, maternal exposure to mainstream CS increa

254 tifungal drug therapy for invasive pulmonary aspergillosis may be further understood.

255 During invasive aspergillosis, mice with a CCR7 deficiency in the hemato

256 own by direct visualization in our zebrafish aspergillosis model in vivo.

257 angiogenesis in a murine invasive pulmonary aspergillosis model.

258 Bronchopulmonary aspergillosis (n = 16), severe asthma with fungal sensit

259 the lungs of neutropenic mice with invasive aspergillosis, NK cells were the major population of cel

260 Allergic bronchopulmonary aspergillosis occurs almost exclusively in cystic fibros

261 e in patients with allergic bronchopulmonary aspergillosis or cystic fibrosis are among the major rec

262 aspergillosis, chronic necrotizing pulmonary aspergillosis, or invasive aspergillosis (IA), depending

263 burdens in a rat model of invasive pulmonary aspergillosis (p<0.05) compared to treatment with the ca

264 During invasive aspergillosis, platelets might be involved in immune def

265 e mortality and morbidity caused by invasive aspergillosis present a major obstacle to the successful

266 The diagnosis of allergic bronchopulmonary aspergillosis relies on criteria first established in 19

267 Diagnosis of invasive aspergillosis remains a significant problem.

268 ly immunosuppressed murine model of invasive aspergillosis resulted in hypovirulence, while analysis

269 rve as an S source during invasive pulmonary aspergillosis since a sulfate transporter mutant strain

270 eve is a novel defense mechanism in invasive aspergillosis that is the result of alterations in DC tr

271 Unlike invasive aspergillosis, the prognosis and outcome of hematologic

272 ection for cryptococcal disease and invasive aspergillosis, the use of molecular (PCR) diagnostics fo

273 Isolated orbital aspergillosis, though rare, should be considered in the

274 ine patients with allergic broncho-pulmonary aspergillosis (two with cystic fibrosis and seven with a

275 Six patients had pulmonary aspergillosis, two each with acute invasive pulmonary as

276 therapeutic decisions when treating invasive aspergillosis using changes in biomarkers as a surrogate

277 igatus and unique susceptibility to invasive aspergillosis via incompletely characterized mechanisms.

278 The incidence of breakthrough invasive aspergillosis was 1.9% (5/262), all with true-positive G

279 Invasive pulmonary aspergillosis was an independent risk factor for 1-year

280 The risk of invasive aspergillosis was assessed with the use of multivariate

281 Probable/proven aspergillosis was associated with a significantly higher

282 nt patients with proven or probable invasive aspergillosis was available from the Transplant-Associat

283 Invasive pulmonary aspergillosis was defined according to European Organiza

284 Probable or proven invasive pulmonary aspergillosis was diagnosed in 14% of our study populati

285 Invasive aspergillosis was documented in 5.2% (6/116) of the pati

286 Aspergillosis was linked to BTK-dependent fungal immunit

287 Increased aspergillosis was observed with ibrutinib monotherapy an

288 and leucopenic mice, the outcome of invasive aspergillosis was similar to that described for A. fumig

289 ance of phagocyte NADPH oxidase in resisting aspergillosis, we found no evidence of this mechanism in

290 investigate the role of CCR7 during invasive aspergillosis, we used a well-characterized neutropenic

291 f two significant resources: the Aspergillus/Aspergillosis website and the Central Aspergillus Data R

292 es and specificities for diagnosing invasive aspergillosis were 81.6% and 91.6%, and 76.9% and 89.4%,

293 , malignant organ infiltration, and invasive aspergillosis were associated with higher hospital morta

294 cortisone-treated mice during early invasive aspergillosis, whereas gene expression returned rapidly

295 spergillus, beyond allergic bronchopulmonary aspergillosis, which require classification.

296 provided a protective effect during invasive aspergillosis, which was further enhanced with the adopt

297 nt sensitivity for the screening of invasive aspergillosis while maintaining methodological simplicit

298 tremely susceptible to mucormycosis, but not aspergillosis, while sodium bicarbonate reversed this su

299 avus is the second leading cause of invasive aspergillosis worldwide.

300 nd effective against IFIs including invasive aspergillosis, zygomycosis, fusariosis, and cryptococcos